Schrodinger, Inc.

Schrödinger, Inc. provides a physics-based computational software platform used to discover and design molecules for therapeutic and materials science applications. The company operates primarily through software licensing and collaborative and proprietary drug discovery programs. Its software products, including Glide, FEP+, and the LiveDesign enterprise informatics platform, assist biopharmaceutical and industrial companies, academic institutions, and government laboratories in modeling molecular interactions, optimizing candidates, and conducting lead optimization. In materials science, Schrödinger offers solutions across organic electronics, semiconductors, aerospace, energy, and chemicals.

The company's commercial software customer base includes leading multinational pharmaceutical firms, biotechnology companies, and academic researchers across more than 1,750 academic institutions worldwide. Direct sales and technical operations span the United States, the European Union, the United Kingdom, Japan, India, and South Korea, supplemented by third-party distribution partners in additional markets including China. The company also maintains a portfolio of collaborative and internal preclinical and clinical drug development programs. Schrödinger's primary corporate offices are not explicitly named in the provided text.

Summary of the business section of Schrodinger's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of February 3, 2026, we had 850 full-time employees, including a total of 363 employees with Ph.D.”